Valiant LaboratoriesNSE:VALIANTLAB -0.32%51 Return-on-Tangible-Equity is 2.26% as of Mar. 2026, which is 87% below its 10-year median of 16.96. GuruFocus rates NSE:VALIANTLAB with a GF Score™ of 51/100 and a GF Value™ of ₹102.90 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 897 Drug Manufacturers companies, Valiant Laboratories ranks worse than 72.58% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Valiant Laboratories's annualized net income for the quarter that ended in Mar. 2026 was ₹70 Mil. Valiant Laboratories's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹3,108 Mil. Therefore, Valiant Laboratories's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 2.26%.
The historical rank and industry rank for Valiant Laboratories's Return-on-Tangible-Equity or its related term are showing as below:
NSE:VALIANTLAB'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -1.2 Med: 16.96 Max: 34.54
Current: -1.14
During the past 6 years, Valiant Laboratories's highest Return-on-Tangible-Equity was 34.54%. The lowest was -1.20%. And the median was 16.96%.
NSE:VALIANTLAB's Return-on-Tangible-Equity is ranked worse than 72.58% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.89
vs NSE:VALIANTLAB: -1.14
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Valiant Laboratories Return-on-Tangible-Equity Related Terms
Valiant Laboratories Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Valiant Laboratories's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:VALIANTLAB vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valiant Laboratories Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Valiant Laboratories's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 2.26% mean?
Valiant Laboratories (NSE:VALIANTLAB) has a Return-on-Tangible-Equity of 2.26% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Valiant Laboratories and its competitors. This is 87% below median its historical median of 16.96. According to the industry distribution chart, Valiant Laboratories ranks #651 out of 897 companies in the Drug Manufacturers industry, placing it in the top 72.6%.
Is Valiant Laboratories' Return-on-Tangible-Equity too high?
Valiant Laboratories' current Return-on-Tangible-Equity of 2.26% is 87% below median its 10-year median of 16.96. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.89. Valiant Laboratories' value of 2.26% is 71.4% below this industry median. Based on the distribution chart, Valiant Laboratories ranks #651 out of 897 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Valiant Laboratories has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valiant Laboratories' Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Valiant Laboratories ranks #651 out of 897 companies for Return-on-Tangible-Equity. This places Valiant Laboratories in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.89. Valiant Laboratories' value of 2.26% is 71.4% below this benchmark. While the company's 10-year median is 16.96 vs. the industry median of 7.89, Valiant Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.89, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valiant Laboratories's current Return-on-Tangible-Equity of 2.26% is 71.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Valiant Laboratories and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valiant Laboratories's current Return-on-Tangible-Equity is 2.26%, which is 87% below median its own 10-year median of 16.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valiant Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Valiant Laboratories (NSE:VALIANTLAB) is currently considered Possible Value Trap. The stock's GF Value™ is ₹102.90, compared to a current price of ₹64.79 — trading 37% below its estimated fair value. The current Return-on-Tangible-Equity is 2.26%, which is 87% below median its 10-year median of 16.96 and 71.4% below the Drug Manufacturers industry median of 7.89. Valiant Laboratories' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Valiant Laboratories (NSE:VALIANTLAB), the current Return-on-Tangible-Equity is 2.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valiant Laboratories (NSE:VALIANTLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Valiant Laboratories stock appears to be undervalued.
The current stock price of ₹64.79 is trading 37% below its estimated GF Value™ of ₹102.90.
GuruFocus considers Valiant Laboratories to be Possible Value Trap.
Key valuation signals for NSE:VALIANTLAB:
Return-on-Tangible-Equity: 2.26% (87% below median its 10-year median of 16.96)
GF Value™: ₹102.90 vs. price of ₹64.79 (37% below fair value)
Industry Position: 71.4% below the Drug Manufacturers median (#651 of 897)
No single metric tells the full story. See the NSE:VALIANTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.
51GF Score
Get the complete analysis for NSE:VALIANTLAB
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VALIANTLAB has been successfully added to your 
